Target Name: CD74
NCBI ID: G972
Review Report on CD74 Target / Biomarker Content of Review Report on CD74 Target / Biomarker
CD74
Other Name(s): CD74 molecule | DHLAG | HLA class II histocompatibility antigen gamma chain (isoform b) | HLA-DR-gamma | Ia-associated invariant chain | HLADG | MHC HLA-DR gamma chain | Ia antigen-associated invariant chain | HLA-DR antigens-associated invariant chain | CD74 variant 2 | CD74 molecule, major histocompatibility complex, class II invariant chain | CD74 antigen | gamma chain of class II antigens | CD74 molecule, transcript variant 2 | Ia-GAMMA | Class-II-associated invariant chain peptide | II | class II MHC-associated invariant chain peptide | p33 | Ii | Gamma chain of class II antigens | CLIP | HLA class II histocompatibility antigen gamma chain | CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) | HG2A_HUMAN

CD74: A Potential Drug Target and Biomarker

CD74 is a protein that is expressed in various tissues throughout the body, including the nervous system, gastrointestinal tract, and skin. It is a member of the transforming growth factor receptor family (TGF-R family) and is involved in several cellular processes, including cell growth, differentiation, and survival. CD74 has also been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. As a result, it has become an attractive target for drug development and research.

CD74's Role in Disease

CD74 has been implicated in several diseases and disorders, including cancer, neurodegenerative disorders, and autoimmune diseases. One of the most significant findings related to CD74 is its involvement in cancer. Several studies have shown that high levels of CD74 are associated with poor prognosis in cancer patients. For example, one study found that patients with high CD74 levels had a significantly lower survival rate in lung cancer compared to those with low CD74 levels.

Another study found that CD74 was highly expressed in the brains of patients with Alzheimer's disease, a neurodegenerative disorder. The researchers suggested that CD74 may play a role in the development and progression of this disease.

In addition to its involvement in cancer and neurodegenerative disorders, CD74 has also been linked to several autoimmune diseases. For example, one study found that CD74 was expressed in the tissues of patients with rheumatoid arthritis, a common autoimmune disorder. The researchers suggested that CD74 may play a role in the development and progression of this disease.

Drug Targeting and Biomarker

CD74 has also been identified as a potential drug target. Several studies have shown that inhibiting CD74 can lead to therapeutic effects in various diseases. For example, one study found that inhibiting CD74 reduced the growth and spread of cancer cells in cell culture. Another study found that inhibiting CD74 reduced the levels of inflammation in the brain in mice with neurodegenerative disorders.

In addition to its potential therapeutic effects, CD74 has also been identified as a potential biomarker. Several studies have shown that measuring levels of CD74 can be used as a diagnostic tool for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, one study found that levels of CD74 were significantly elevated in the brains of patients with Alzheimer's disease compared to those without the disease.

Conclusion

CD74 is a protein that has been implicated in several diseases and disorders. Its role in cancer, neurodegenerative disorders, and autoimmune diseases makes it an attractive target for drug development and research. Further studies are needed to fully understand the role of CD74 in these diseases and to develop effective therapies.

Protein Name: CD74 Molecule

Functions: Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. Serves as cell surface receptor for the cytokine MIF

The "CD74 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD74 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5